Sanjivani Paranteral Peer Comparison

Sanjivani Paranteral Ltd. is underperforming relative to its peers across key financial metrics, revealing a lack of growth and profitability. The peer group shows strong players like Sun Pharmaceuticals and Mankind Pharma, which highlight a stark contrast in financial health and growth prospects. While Sanjivani has a low debt ratio, it also exhibits no revenue or EPS growth, putting it at a disadvantage.

• • Sanjivani has 0% revenue growth and no profitability metrics reported.
• • Sun Pharmaceutical and Mankind Pharma are leading in revenue growth and profitability.
• • Divi's Laboratories shows high PE but weak revenue growth, indicating possible overvaluation.

• • Sun Pharmaceutical Industries Ltd.: Highest revenue growth (YoY 8.42%) and strong profitability metrics (ROE 16.13%).
• • Mankind Pharma Ltd.: Best growth trajectory with outstanding 3-Year revenue growth (155.25%) and solid profitability (ROE 23.15%).
• • Dr. Reddy's Laboratories Ltd.: Strong profitability indicators (ROE 21.76%) and attractive valuation metrics (PE 15.50).